What is Inotrem?
Inotrem is a specialized biotechnology firm dedicated to restoring immune balance in patients facing critical inflammatory crises. Its flagship therapeutic candidate, INO-01, also known as nangibotide, represents a first-in-class peptidic inhibitor of the TREM-1 pathway. This mechanism is specifically engineered to mitigate the dysregulated immune responses observed in conditions such as septic shock and severe COVID-19. Beyond its therapeutic portfolio, Inotrem distinguishes itself through a strategic partnership with Roche Diagnostics, providing a companion diagnostic tool that ensures precision in patient selection. This integrated approach to medicine positions Inotrem as a critical player in the intersection of biopharmaceuticals and diagnostic innovation.
How much funding has Inotrem raised?
Inotrem has raised a total of $85.6M across 2 funding rounds:
Series A
$21.8M
Series B
$63.7M
Series A (2014): $21.8M with participation from Transfert Initiative, Sofinnova Partners, and Edmond de Rothschild
Series B (2020): $63.7M led by Kreos Capital, Sofinnova Partners, Invus, Bpifrance, Morningside Ventures, Andera Partners, BiomedInvest, and Fountain Healthcare Partners
Key Investors in Inotrem
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. The firm acts as a hands-on company builder across the entire value chain of life sciences investments.
Edmond de Rothschild
Edmond de Rothschild, founded in 1923 and headquartered in France, is an investment banking firm offering various financial services and solutions.
Kreos Capital
Kreos Capital Group Ltd is a company that specializes in finance, providing investment services and business management since 1998.
What's next for Inotrem?
With the support of major enterprise-level funding, Inotrem is poised to transition its lead assets through advanced clinical stages. The strategic focus remains on validating the efficacy of nangibotide in broader patient populations while refining its companion diagnostic platform. As the company scales, the emphasis will likely shift toward regulatory milestones and potential commercialization pathways. The continued participation of seasoned life sciences investors suggests a long-term commitment to establishing Inotrem as a leader in the treatment of acute inflammatory disorders, potentially reshaping the therapeutic landscape for critical care medicine.
See full Inotrem company page
